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The propensity of plaque to disrupt is a major determinant of future ischemic events.
Although they are distinct from one another, the atherosclerotic and thrombotic processes
appear to be interdependent and may be integrated under the term “atherothrombosis.” It is
now clear that plaque composition, rather than the percent stenosis, is a major determinant
of plaque vulnerability. Plaque disruption seems to depend on both passive and active
phenomena and is not purely mechanical. Inflammation (activation of monocytes/
macrophages) is a major determinant of both plaque vulnerability and thrombogenicity as
they relate to plaque disruption. In one-third of acute coronary syndromes, there is, however,
no plaque disruption but only superficial erosion of a markedly stenotic, fibrotic plaque. In
these cases, thrombus formation may be exacerbated by a hyperthrombogenic state present in
patients with certain systemic risk factors. The endothelium plays a pivotal role in vascular
homeostasis and hemostasis. This dynamic organ regulates blood thrombogenicity as well as
contractile, secretory, and mitogenic activities in the vessel wall. Some classic risk factors
induce endothelial dysfunction by reducing the bioavailability of nitric oxide, increasing tissue
endothelin-1, and activating pro-inflammatory signaling pathways. Vascular hemostasis,
which is the maintenance of blood fluidity and vascular integrity, is achieved by counter-
balancing the intrinsic clotting tendency of blood. As a consequence of the central role of
endothelial cells in hemostatic control, a dysfunctional endothelium will generate a pro-
thrombotic environment favoring development of atherosclerotic lesions and thrombotic
complications. (J Am Coll Cardiol 2003;41:7S–14S) © 2003 by the American College of
Cardiology Foundation
Crucial advances in the understanding of the pathogenesis
of atherosclerosis have been achieved during the last two
decades. The two major historical hypotheses of pathogen-
esis, the “incrustation” and “lipid” hypotheses, have evolved
into new concepts that integrate several factors contributing
to the initiation and evolution of this disease (1–4). Dys-
functional endothelium and inflammation are now known
to have pivotal roles in the initiation and progression of
atherosclerotic disease and are considered to be promoters of
the disease (Fig. 1). The atherosclerotic and thrombotic
processes appear somewhat interdependent and may there-
fore be integrated under the term “atherothrombosis.”
Atherothrombosis is a systemic disease involving the
intima of large- and medium-sized arteries, including the
aorta, carotid, coronary, and peripheral arteries. Secondary
changes may occur in the underlying media and adventitia,
particularly in the more advanced stages of the disease (5).
The biological processes involving the media are probably
responsible for vessel wall remodeling (outward expansion)
during plaque growth and for plaque disruption. Disrupted
atherosclerotic plaques exhibit a higher incidence of eccen-
tric expansion (also known as positive remodeling), larger
plaque areas, and a higher incidence of disruption of the
internal elastic lamina compared with non-disrupted
plaques (6).
For unknown reasons, some arteries, such as the brachial
and internal mammary, are highly resistant to atherothrom-
bosis. In addition, although the epicardial coronary arteries
appear to be the most susceptible, intramyocardial arteries
are highly resistant to atherosclerosis.
Atherothrombotic plaques are composed mainly of con-
nective tissue extracellular matrix (including collagen, pro-
teoglycans, fibronectin elastic fibers), lipids (crystalline cho-
lesterol, cholesteryl esters, phospholipids), inflammatory
cells (monocyte-derived macrophages, T-lymphocytes),
smooth muscle cells (SMC), thrombi, and calcium deposits
(7,8). Varying proportions of these components occur in
different plaques, thus giving rise to a spectrum of lesions.
Post-mortem studies have revealed striking heterogeneity in
plaque morphology and composition in the various vessel
territories, even in the same individual.
Evidence indicates that both plaque composition and its
propensity to rupture are major determinants of future
ischemic events. Disruption-prone plaques in the coronary
arteries, the so-called “high-risk” or “vulnerable” plaques,
tend to have a thin fibrous cap, a large lipid core, and a high
macrophage content (9). Acute coronary syndromes (ACS)
often result from disruption of such modestly stenotic,
lipid-rich, vulnerable plaques, which are not detectable by
X-ray angiography, leading to thrombotic complications
(10). By contrast with vulnerable plaques in the coronary
artery, the disruption-prone, high-risk plaques in the ca-
rotid arteries are severely stenotic. Therefore, viewed from
the more global perspective of systemic atherothrombotic
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disease, the term “high-risk” plaque, rather than the classic
term “vulnerable” plaque (that implies only the presence of
a lipid-rich core) is more appropriate for defining a
disruption-prone plaque.
There is striking heterogeneity in the composition of
human atherothrombotic plaques, even within the same
individual. Therefore, reliable, noninvasive imaging tools
that are able to detect early atherothrombotic disease in the
various regions and characterize the composition of the
plaques are clinically desirable (11). Such tools will improve
our understanding of the pathophysiological mechanisms
underlying the atherothrombotic processes and allow us to
risk-stratify the disease more effectively. Also, these tools
may permit optimal tailoring of treatment and allow direct
monitoring of the vascular response.
Initiation of atherothrombotic disease: the role of the
endothelium. The past two decades have highlighted the
pivotal role of the endothelium in preserving vascular
homeostasis (by controlling vasomotion) and hemostasis (by
balancing pro- and anti-thrombotic properties). The endo-
thelium, the inner layer of blood vessels, is a dynamic
autocrine and paracrine organ. It regulates contractile,
secretory, and mitogenic activities in the vessel wall, as well
as blood thrombogenicity, by producing several locally active
substances (Fig. 2).
“Vascular homeostasis,” defined as the ability of the
vascular system to maintain normal hemorheological con-
ditions, is guaranteed by adequate control of vasomotion
through the balanced production of potent vasodilators such
as nitric oxide (NO) and vasoconstrictors such as
endothelin-1 (ET-1).
Chronic minimal injury to the arterial endothelium is
physiological and is often the result of a disturbance in the
pattern of blood flow at bending points and near bifurca-
tions of the arterial tree (2). The endothelium responds to
mechanical and chemical signals from the blood by releasing
mediators that modulate vascular tone and structure, platelet
function, coagulation, and monocyte adhesion (Fig. 2).
Some of the classic cardiovascular risk factors have been
recognized to induce endothelial dysfunction by reducing
the bioavailability of NO, increasing tissue ET-1 content
(12), and activating pro-inflammatory signaling pathways
such as nuclear factor kappa B (13). The nuclear factor
kappa B signaling transduction pathway is an essential
regulator of the transcription of a number of pro-
inflammatory genes, such as those that lead to the expres-
sion of many cytokines, enzymes, and adhesion molecules
(i.e., intercellular adhesion molecule 1 [ICAM-1], vascular-
cell adhesion molecule 1 [VCAM-1], and E-selectin) (14).
In hypercholesterolemia, for example, endothelium-
dependent relaxation is impaired, while contraction and
adhesion of monocytes and platelets are enhanced. How-
ever, pharmacologic correction of hyperlipidemia by statins
has been shown to improve or normalize endothelial func-
tion in patients (15). Recent studies have demonstrated that
patients with coronary endothelial vasomotor dysfunction,
in the presence of a variety of stimuli, have an increased risk
of clinical events, definitively linking these cardiovascular
risk factors to atherogenesis and clinical events (16,17).
“Vascular hemostasis,” defined as the ability of the vas-
cular system to maintain blood fluidity and vascular integ-
rity, is achieved by counter-balancing the intrinsic clotting
tendency of the blood (Fig. 2). Von Willebrand factor is one
protein involved in the clotting tendency of the blood as it
mediates platelet-to-platelet activity and interactions be-
tween platelets and the vessel wall (18). Both types of
interaction are vital in maintaining the balance between
bleeding and clotting. In physiological conditions, the
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
CRP  C-reactive protein
ET  endothelin
ICAM  intercellular adhesion molecule
LDL  low-density lipoprotein
MMP  matrix metalloproteinase
NO  nitric oxide
PGI  prostaglandin inhibitor
SMC  smooth muscle cell(s)
TF  tissue factor
TFPI  tissue factor pathway inhibitor
TIMP  tissue inhibitor of metalloproteinases
VCAM  vascular cell adhesion molecule
Figure 1. Link between cardiovascular (CV) risk factors, endothelial
dysfunction, inflammation, and acute coronary syndromes. Endothelial
dysfunction can be caused by many pro-inflammatory atherogenic factors
(i.e., oxidative stress, low shear stress, glycation end-products, smoking,
probably infections). Initially, endothelial nitric oxide synthesis is de-
creased, leading to impairment of endothelial-dependent vasorelaxation;
this represents one of the earliest changes of atherosclerosis. Endothelial
cells thereafter increase expression of adhesion molecules (VCAM,
ICAM-1, and so forth), which facilitate monocyte and platelet adherence
to the vessel wall through their cell-surface integrin receptors. Inflamma-
tory cells are responsible for the release of TF, the major trigger of the
coagulation cascade. ACE  angiotensin converting enzyme; CNP  c-type
natriuretic peptide; ICAM-1  intercellular adhesion molecule; MCP-1 
monocyte chemoattractant protein-1; NFk  nuclear factor kappa; PDGF 
platelet-derived growth factor; PGI2  prostaglandin; TGF  transforming
growth factor; VCAM  vascular cell adhesion molecule.
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normal endothelium actively supports the fluid state of
flowing blood and prevents the activation of circulating
cells. In this context, NO and prostaglandin are the most
recognized platelet inhibitors of all the endothelial-borne
agents.
Endothelial dysfunction and breaches of endothelial
integrity trigger a series of biochemical and molecular
reactions that serve to stop blood flow and repair the vessel
wall. The first steps in repairing the vessel wall and
preventing excessive blood loss are vasoconstriction, platelet
adhesion, and fibrin formation at the place of the injury,
which causes a hemostatic aggregate to form. Platelet
aggregation is mediated through several agents, including
adenosine diphosphate, thromboxane A2, and matrix
metalloproteinase-2 (MMP-2). Also, the extrinsic coagula-
tion cascade is activated through the interaction between
vascular tissue factor (TF) and flowing blood, leading to the
in vivo generation of thrombin, a major agonist of platelet
activation and thrombin formation. Fibrin interacts with
activated platelets to form a mesh structure that is indis-
pensable for the adequate consistency and stability of the
adhesive mural thrombus.
Because endothelial cells play a central role in controlling
hemostasis, a dysfunctional endothelium will generate a
pro-thrombotic environment favorable to the development
of atherosclerotic lesions and thrombotic complications.
Atherosclerotic plaque progression. Endothelial dysfunc-
tion is considered the precursor that initiates the atheroscle-
rotic process and is characterized by the increased expression
of adhesion molecules (e.g., selectins, VCAMs, and
ICAMs) that participate in “homing” and infiltrating
monocytes (3,15). The monocytes migrate into the sub-
endothelium, where they transform into macrophages
(Fig. 2).
This differentiation process includes the up-regulation of
various receptors, including CD36 and the scavenger recep-
Figure 2. Pathogenesis of plaque development. Endothelial dysfunction and inflammatory processes are crucial in the initiation and progression of
atherosclerotic lesions. The major goal of endothelial activity is to maintain constant hemostatic and hemorheologic conditions through a balanced
production of several vasoactive and thrombotic/antithrombotic substances. Arrow  promotion; dashed line  inhibition. CAM  cell adhesion
molecules; CRP  C-reactive protein; ET  endothelin; FDP  fibrin degrading products; MCP-1  monocyte chemoattractant protein-1; M-CSF 
macrophage colony-stimulating factor; MMPmetalloproteinase; NO nitric oxide; PAI-1 plasminogen activator inhibitor-1; PGI2 prostaglandin;
SMC  smooth muscle cells; TF  tissue factor; tPA  tissue plasminogen activator; TXA2  thromboxane A2; VEGF  vascular endothelial growth
factor. Reproduced with permission from Lippincott, Williams and Wilkins.
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tor A, that are responsible for the internalization of oxidized
low-density-lipoprotein (LDL). Once they are lipid-
enriched, macrophages transform into foam cells leading to
the formation of fatty streaks. These activated macrophages
release mitogens and chemo-attractants that perpetuate the
process by recruiting additional macrophages and vascular
SMC from the media into the injured media (Fig. 2). This
may eventually compromise the vascular lumen. The re-
cruited SMC and macrophages will significantly contribute
to plaque growth, not only by increasing their number but
also by synthesizing extracellular matrix components. The
ratio between SMC and macrophages plays an important
role in plaque vulnerability because of the lytic activity
involved. Macrophages are able to elaborate MMPs. These
enzymes contribute to plaque disruption and thrombus
formation by digesting the extracellular matrix (4).
The rate of progression of atherosclerotic lesions is
variable and poorly understood. It might be expected that
atherogenesis and lesion progression are linear. However,
coronary angiographic studies have demonstrated that pro-
gression in humans is neither linear nor predictable. An
analysis of various studies unexpectedly revealed that over
75% of myocardial infarcts occur in areas supplied by mildly
stenosed (50%) coronary arteries identified in a previous
angiogram (19). Nevertheless, on the basis of pathological
findings, plaque development can be divided into slow or
rapid progression.
SLOW PLAQUE PROGRESSION. As previously discussed, en-
dothelial dysfunction underlies slow progression by facili-
tating the internalization of circulating lipids and mono-
cytes, ultimately leading to foam cell formation and release
of mitogenic and growth factors. The continuing infiltration
of monocytes/macrophages into plaques is partly dependent
on factors such as endothelial adhesion molecules (i.e.,
VCAM-1), monocyte chemotactic protein-1, monocyte
colony, stimulating factor, and interleukin-2 for lympho-
cytes. Macrophages may eventually undergo apoptotic death
in what appears to be a defensive strategy to protect the
vessel wall from an excess accumulation of lipoproteins.
Although it is still uncertain whether apoptotic death
triggers the release of MMPs, this phenomenon probably
leads to the shedding of membrane microparticles, causing
exposure of phosphatidylserine on the cell surface and
conferring a potent procoagulant activity. The shed particles
account for almost all of the TF activity present in plaque
extract and may be a major contributor in the initiation of
the coagulation cascade and thrombosis after plaque disrup-
tion (20). Such phenomena initiate the phase of rapid
plaque growth.
RAPID PLAQUE GROWTH. Rapid plaque growth is
thrombus-mediated. Evidence suggests that plaque rupture,
subsequent thrombosis, and fibrous thrombus organization
are also important in the progression of atherosclerosis in
both asymptomatic patients and those with stable angina.
Plaque disruption with subsequent change in plaque geom-
etry and thrombosis results in a complicated lesion. Such a
rapid change in atherosclerotic plaque geometry may result
in acute occlusion or subocclusion with clinical manifesta-
tions of unstable angina or other ACS. More frequently,
however, the rapid changes seem to result in a mural
thrombus without evident clinical symptoms. This type of
thrombus may be a main contributor to the progression of
atherosclerosis. A number of local and systemic circulating
factors may influence the degree and duration of thrombus
deposition at the time of disruption of the coronary plaque
(Table 1) (21). The thrombus may then either be partially
lysed or become replaced in the process of vascular repair
response (Fig. 3).
ACS and plaque disruption. Angiographically, fairly small
coronary lesions may be associated with acute progression to
severe stenosis or total occlusion and may eventually account
for as many as two-thirds of the patients who develop
Table 1. Factors Modulating Platelet-Arterial Wall Interaction
Local rheologic conditions
Blood flow, shear stress, etc.
Nature of the exposed substrate
Degree of injury (mild vs. severe arterial injury)
Composition of atherosclerotic plaque
Residual mural thrombus
Systemic thrombogenic factors
Hypercholesterolemia
Catecholamines (smoking, cocaine, stress, etc.)
Smoking
Diabetes
Homocysteine
Lipoprotein (a)
Infections (Chlamydia pneumoniae, Helicobacter pylori, CMV)
Hypercoagulable state (1 fibrinogen, 1 vWF, 1 TF, 1 Factor VII,
1 F1.2)
Defective fibrinolytic state (1 PAI-1, 2 tPA, 2uPA, etc.)
CMV cytomegalovirus; TF tissue factor; vWF von Willebrand factor; F1.2
prothrombin fragment F1  2; PAI-1  plasminogen activator inhibitor 1; tPA 
tissue plasminogen activator; uPA  urokinase.
Figure 3. Acute coronary syndromes typically derive from atherosclerotic
plaque disruption. Lipid-rich lesions (A) account for 70% of acute coronary
occlusions. The shoulder regions of the plaque often have a thinner fibrous
cap that is highly infiltrated with macrophages and are prone to rupture.
Mural thrombi on disrupted or ulcerated plaques may progress to occlusive
thrombi or be partially lysed and be replaced in the process of organization
by the vascular repair response (B).
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unstable angina or other ACS (19). The degree of plaque
disruption (ulceration, fissure, or erosion) or substrate ex-
posure is a key factor in determining thrombogenicity at the
local arterial site. In fact, thrombogenicity of a disrupted
human atherosclerotic plaque can be predicted by its content
on TF activity. In an experimental setting in which dis-
rupted human aortic plaques were exposed to flowing blood
at high shear rates, the lipid core was found to be the most
thrombogenic of the various plaque components. The lipid
core also showed the most intense TF staining when
compared with other components (22,23). Residual mural
thrombus also appears to be highly thrombogenic (24).
The unpredictable and episodic progression is most
probably caused by disruption of lipid-rich type IV and type
V plaques with subsequent thrombus formation. This
changes the plaque geometry and leads to acute or inter-
mittent silent plaque growth or acute symptomatic, occlu-
sive coronary syndromes (Fig. 3). Plaque disruption seems
to depend on both passive and active phenomena.
PASSIVE PROCESS—PHYSICAL AND STRUCTURAL VARI-
ABLES. Passive plaque disruption is related to physical
forces, and it occurs most frequently where the fibrous cap
is weakest, that is, where it is thinnest and most heavily
infiltrated by foam cells. For eccentric plaques, this is often
the shoulder or between the plaque and the adjacent vessel
wall. Three major factors determine the vulnerability of the
fibrous cap: 1) circumferential wall stress or cap “fatigue”; 2)
location, size, and consistency of the atheromatous core; and
3) blood-flow characteristics, particularly the impact of flow
on the proximal aspect of the plaque (i.e., configuration and
angulation of the plaque) (25).
ACTIVE PROCESS—MMPs AND TF. The process of plaque
disruption is, however, not purely mechanical. Inflamma-
tion, for instance, plays a pivotal role in plaque disruption.
Atherectomy specimens from patients with ACS reveal
areas very rich in macrophages (9), and these cells are
capable of degrading extracellular matrix by secretion of
proteolytic enzymes such as MMPs (collagenases, gelati-
nases, stromelysins, and others). These enzymes may
weaken the fibrous cap and predispose it to rupture (26).
Indeed, the MMPs and their co-secreted tissue inhibitors of
metalloproteinases (TIMP), TIMP-1 and TIMP-2, are
crucial for vascular remodeling. Certain MMPs may be
particularly active in destabilizing plaques.
Tissue factor, a small-molecular-weight glycoprotein,
initiates the extrinsic clotting cascade and is believed to be a
major regulator of coagulation, hemostasis, and thrombosis
(27). Recent studies have demonstrated an increased TF
expression either directly in the coronary arteries or indi-
rectly in the plasma of patients with unstable angina or
myocardial infarction compared with patients with stable
angina (20). Co-localization analysis of coronary atherec-
tomy specimens (culprit lesions) from patients with unstable
angina showed a strong relationship between TF and
macrophages (28). This relationship suggests a cell-
mediated thrombogenicity in patients with unstable angina
and ACS. Furthermore, recent observations obtained from
similar human coronary and carotid artery specimens
showed that TF is often co-localized in macrophage apo-
ptotic death and released microparticles rather than in
biologically active macrophages (29). Specific inhibition of
vascular TF by TF pathway inhibitor (TFPI) was associated
with a significant reduction of acute thrombus formation in
lipid-rich plaques (Fig. 4) (30). Interestingly, in the pig
model of arterial injury, TFPI administration during percu-
taneous coronary angioplasty prevented acute thrombus
formation without increasing the bleeding complications,
and it reduced intima hyperplasia without affecting SMC
growth (Fig. 5) (31). Such observations document the role
of TF activity in acute arterial thrombosis after atheroscle-
rotic plaque disruption and may lead to the development of
a new therapeutic strategy in the prevention of ACS.
ACS and blood thrombogenicity. In one-third of ACS,
particularly in sudden coronary death, there is no disruption
of a small lipid-rich plaque but only a superficial erosion of
a markedly stenotic and fibrotic plaque (32). Thrombus
formation in such cases may depend on a hyperthrombo-
genic state triggered by systemic factors (Table 1). Indeed,
Figure 4. Effect of the inhibition of vascular tissue factor activity by
recombinant TF pathway inhibitor (rTFPI) on the thrombogenicity of
human atherosclerotic lesions (30). (A) Representative immunophotograph
of control. (B) rTFPI-treated human lipid-rich atherosclerotic lesions.
rTFPI was associated with a significant reduction of acute thrombus
formation, both platelet and fibrin(ogen) thrombus component, in human
lipid-rich plaques. Reproduced with permission from Lippincott, Williams
and Wilkins.
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systemic factors, including elevated LDL cholesterol, ciga-
rette smoking, hyperglycemia, hemostasis, and others, are
associated with increased blood thrombogenicity (5).
CARDIOVASCULAR RISK FACTORS AND HYPERTHROMBOGE-
NICITY. Elevated LDL cholesterol levels have been found
to increase blood thrombogenicity and growth of thrombi
under defined rheology conditions (33,34). Reducing LDL
cholesterol levels with statins was shown to decrease throm-
bus growth by approximately 20% (34). The question is, to
what extent does such an antithrombotic effect—for exam-
ple, with statins (documented in large prospective clinical
trials)—contribute to the reduction of total vascular events,
including death, coronary events, and stroke (35,36).
Smoking increases sympathetic nerve activity (37) and,
therefore, catecholamine release, which may potentiate
platelet activation and increase fibrinogen levels.
Catecholamine-dependent effects in the circulating blood
could explain not only the increase in the incidence of
sudden death and acute cardiovascular events after emo-
tional and physical stress but also the circadian distribution
of these events (38).
Diabetic patients, especially those whose diabetes is
poorly controlled, have increased blood thrombogenicity
(39). Platelets from patients with diabetes have been shown
to have increased reactivity and hyper-aggregability and
expose a variety of activation-dependent adhesion proteins
(40). Abnormal platelet function is reflected by increased
platelet consumption and increased accumulation of plate-
lets on the altered vessel wall.
TF PATHWAY AND HYPERTHROMBOGENICITY. Recent ob-
servations indicate that the hyperthrombogenic states asso-
ciated with high LDL cholesterol, cigarette smoking, and
diabetes may share a common biological pathway: activation
of leukocyte-platelet interactions associated with the release
of TF and thrombin activation. Specifically, more
leukocyte-platelet aggregates circulate in the blood of pa-
tients with diabetes mellitus. The pro-thrombotic state in
diabetes is also associated with an increased expression of
monocyte procoagulant activity in the presence of diabetic
microalbuminuria. The increased procoagulant activity in
diabetes is attributed to leukocytes, which may in part
activate the TF pathway (41) and contribute to the high
blood thrombogenicity in diabetic patients (40).
Recent studies have found increased levels of circulating
TF antigen in patients with cardiovascular disease. Circu-
lating TF has been associated with increased blood throm-
bogenicity in patients with unstable angina (42) and chronic
coronary artery disease (43). Blood levels of TF have also
been shown to predict outcome in patients with unstable
angina (44).
As previously described, lipid-rich atherosclerotic plaques
contain TF associated with macrophages within the lesion
(23) and may account, in large part, for the high thrombo-
genicity of these lesions. Tissue factor has also been iden-
tified within thrombi formed in the coronary arteries. In
addition, specific inhibition of the TF pathway by TFPI
significantly reduces plaque thrombogenicity (30). The
TFPI is usually expressed in the adventitial layer of large
arteries, and in atherosclerotic vessels, TFPI is expressed by
macrophages in focal areas in the plaque. Local production
of TFPI may regulate pro-coagulant activity and thrombotic
events within atherosclerotic plaques (45).
Aside from apoptotic macrophages and microparticles
from atherosclerotic plaques, activated monocytes in the
circulating blood seem to be a source of TF microparticles
and may represent the result of activation by the previously
mentioned risk factors and others, thus contributing to
thrombotic events. Within the context of the possibly
pro-inflammatory or pro-thrombotic effects on the circulat-
ing blood exerted by high LDL cholesterol, cigarette smok-
ing, and diabetes, there is evolving evidence that circulating
monocytes and white blood cells may be involved in TF
expression and thrombogenicity (46). Indeed, the predictive
value for coronary events of high levels of C-reactive protein
(CRP) may be a manifestation of such systemic phenomena
(47).
C-reactive protein, similar to fibrinogen, is a protein of
the acute-phase response and a sensitive marker of low-
grade inflammation. Increased levels of CRP have been
reported to predict acute coronary events (47), and CRP
seems to be a useful marker in the prediction of thrombotic
events. Whether CRP reflects the inflammatory component
of atherosclerotic plaques or of the circulating blood, and
whether it is a surrogate marker or a biologically active
element in plaque development of thrombus formation at
Figure 5. Inhibition of tissue factor (TF) by TF pathway inhibitor (TFPI)
reduces thrombus formation and intima hyperplasia after porcine coronary
angioplasty (49). Administration of TFPI during coronary angioplasty
prevented acute thrombus formation (B). Note the presence of mural
thrombus (black arrow) and intramural hemorrhage (white arrow) in the
control animal (A) despite similar vascular injury, as confirmed by the
disruption of the internal elastic lamina and part of the media present in
both A and B. Similarly, TFPI significantly reduced the proliferative
response in porcine coronary arteries (D) 28 days after angioplasty as
compared with control animals (C). Adapted from Roque M, et al. J Am
Coll Cardiol 2000;36:2303–10 (31).
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the site of the atherosclerotic vessel, are not known (48).
However, recent studies support the hypothesis that CRP is
an activator of blood monocyte and vessel-wall endothelial
cells (49).
Conclusions. Increasing evidence supports the centrality of
the role of endothelial dysfunction in the initiation and
progression of atherothrombotic disease. Inflammation is
involved in plaque disruption—mainly through the produc-
tion of enzymes able to digest the fibrous cap—and also in
the production of TF, which is the most important modu-
lator of blood coagulation and thrombosis. Endothelial
dysfunction and the release of TF by inflammatory and
apoptotic cells are essential to hemostatic control and,
therefore, closely related to the thrombotic process. In
addition, a pro-inflammatory effect of the circulating blood
has been postulated. In this context, a treatment strategy
designed to improve endothelial dysfunction and reduce
inflammation at the level of the vessel wall, as well as in the
circulating blood, may have important implications in the
prevention of ACS. There is a need for further investigation
into the effect that certain risk factors have on the activation
of inflammation in the vessel wall and circulating blood, and
such an investigation would probably demonstrate that TF
and CRP are the key local and systemic factors in the
process of atherothrombosis.
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